{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:45:24Z","timestamp":1782301524709,"version":"3.54.5"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib. This review aimed to establish whether sufficient evidence exists for the routine or selective therapeutic drug monitoring of pazopanib in adult patients with approved indications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic search of the PubMed and Web of Science databases using search terms related to pazopanib and therapeutic drug monitoring yielded 186 and 275 articles, respectively. Ten articles associated with treatment outcomes or toxicity due to drug exposure were selected for review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The included studies were evaluated to determine the significance of the relationship between drug exposure\/C<jats:sub>trough<\/jats:sub> and treatment outcomes and between drug exposure and toxicity. A relationship between exposure and treatment outcomes was observed in 5 studies, whereas the trend was nonsignificant in 4 studies. A relationship between exposure and toxicity was observed in 6 studies, whereas 2 studies did not find a significant relationship; significance was not reported in 3 studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Sufficient evidence supports the therapeutic drug monitoring of pazopanib in adult patients to improve its efficacy and\/or safety in the approved indications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001206","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T18:02:32Z","timestamp":1715277752000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review"],"prefix":"10.1097","volume":"46","author":[{"given":"Miroslav","family":"Turjap","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Hospital Ostrava, Ostrava, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pelcov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Gregorov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"\u0160mak","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0160tingl","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Pe\u0161","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-6711","authenticated-orcid":false,"given":"Jan","family":"Ju\u0159ica","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;"},{"name":"Masaryk Memorial Cancer Institute, Brno, Czech Republic; and"},{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bcp.13327","article-title":"Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib","volume":"83","author":"Lankheet","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur J Clin Pharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.14185","article-title":"Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose","volume":"86","author":"Westerdijk","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.1016\/j.clgc.2018.12.001","article-title":"Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma","volume":"17","author":"Noda","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R9-20250603","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090927","article-title":"Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC","volume":"14","author":"Ozbey","year":"2021","journal-title":"Pharmaceuticals"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.21873\/invivo.11922","article-title":"Association of genetic polymorphisms with afatinib-induced diarrhoea","volume":"34","author":"Sogawa","year":"2020","journal-title":"In Vivo"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Deng","year":"2013","journal-title":"Xenobiotica"},{"key":"R13-20250603","first-page":"1719","article-title":"Drug-drug interactions in patients using tyrosine kinase inhibitors: a multicenter retrospective study","volume":"24","author":"Ergun","year":"2019","journal-title":"J Buon"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00228-020-02828-w","article-title":"Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors","volume":"76","author":"Azam","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jgo.2021.02.006","article-title":"VOTRAGE study: phase I dose-escalation study of pazopanib in unfit older patients","volume":"12","author":"Mourey","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.2010.158","article-title":"An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors","volume":"88","author":"Goh","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-019-03784-8","article-title":"Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38","volume":"83","author":"Iwase","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.dmpk.2019.08.001","article-title":"Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib","volume":"34","author":"Taguchi","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"R21-20250603","first-page":"200","article-title":"Importance of therapeutic drug monitoring to detect drug interaction between pazopanib and warfarin: a case report","volume":"23","author":"Takasaki","year":"2020","journal-title":"J Pharm Pharmaceut Sci."},{"key":"R22-20250603","first-page":"10339","article-title":"Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab","volume":"27","author":"Zhong","year":"2020","journal-title":"Can J Urol"},{"key":"R23-20250603","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12090852","article-title":"Biological role of pazopanib and sunitinib aldehyde derivatives in drug-induced liver injury","volume":"12","author":"Maillard","year":"2022","journal-title":"Metabolites"},{"key":"R24-20250603","first-page":"e32474","article-title":"Pazopanib-induced liver injury in patients with metastatic renal cell carcinoma: a report of two cases","volume":"14","author":"Ouchi","year":"2022","journal-title":"Cureus"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn J Clin Oncol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/bcp.15576","article-title":"Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study","volume":"89","author":"Zelmat","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","article-title":"Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients","volume":"58","author":"Bins","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R28-20250603","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-023-01260-4","article-title":"CYP3A4*22 genotype-guided dosing of kinase inhibitors in cancer patients","author":"van Eerden","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clgc.2019.09.013","article-title":"Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes","volume":"18","author":"Henriksen","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/annonc\/mdt394","article-title":"Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms","volume":"24","author":"Motzer","year":"2013","journal-title":"Ann Oncol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-018-3665-x","article-title":"In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia","volume":"82","author":"Qosa","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br J Cancer"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"37599","DOI":"10.18632\/oncotarget.9229","article-title":"Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma","volume":"7","author":"Bianconi","year":"2016","journal-title":"Oncotarget"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"R35-20250603","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3598","article-title":"Therapeutic drug monitoring of pazopanib: using cost-neutral PK-guided interventions to optimize exposure","volume":"38","author":"Groenland","year":"2020","journal-title":"J Clin Oncol"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"S1125","DOI":"10.1016\/j.annonc.2021.08.879","article-title":"Pazopanib exposure in advanced soft tissue and bone sarcoma: a pharmacokinetic\/pharmacodynamic analysis","volume":"32","author":"Minot","year":"2021","journal-title":"Ann Oncol"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1200\/JCO.2017.35.15_suppl.4564","article-title":"Pazopanib exposure response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy","volume":"35","author":"Sternberg","year":"2017","journal-title":"J Clin Oncol"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R39-20250603","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3048","article-title":"Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC)","volume":"28","author":"Suttle","year":"2010","journal-title":"J Clin Oncol"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","article-title":"Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization","volume":"80","author":"Verheijen","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/pros.23899","article-title":"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer","volume":"79","author":"George","year":"2019","journal-title":"Prostate"},{"key":"R43-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100217","article-title":"Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)","volume":"6","author":"Eriksson","year":"2021","journal-title":"ESMO Open"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/COC.0000000000000999","article-title":"The efficacy and safety of pazopanib plus chemotherapy in treating recurrent or persistent ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J Med Chem"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/bcp.14580","article-title":"Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib","volume":"87","author":"Fukudo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics14061224","article-title":"Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients","volume":"14","author":"Minot-This","year":"2022","journal-title":"Pharmaceutics"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","article-title":"Individualized pazopanib dosing: a prospective feasibility study in cancer patients","volume":"22","author":"Verheijen","year":"2016","journal-title":"Clin Cancer Res."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1248\/bpb.b19-00560","article-title":"Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer","volume":"43","author":"Tanaka","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13225780","article-title":"Intra-tumoral pharmacokinetics of pazopanib in combination with radiotherapy in patients with non-metastatic soft-tissue sarcoma","volume":"13","author":"Molenaar-Kuijsten","year":"2021","journal-title":"Cancers"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","article-title":"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FTD.0000000000000141","article-title":"Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study","volume":"37","author":"de Wit","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FTD.0000000000000767","article-title":"Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs","volume":"42","author":"Janssen","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40262-020-00863-5","article-title":"Cost-neutral optimization of pazopanib exposure by splitting intake moments: a prospective pharmacokinetic study in cancer patients","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","article-title":"A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors","volume":"88","author":"Heath","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cpt.1515","article-title":"The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study)","volume":"106","author":"Lubberman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int J Cancer"},{"key":"R59-20250603","first-page":"127","article-title":"Clinical importance of blood drug concentration of oral molecular targeted drugs for renal cell carcinoma","volume":"24","author":"Takasaki","year":"2021","journal-title":"J Pharm Pharmaceut Sci"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0000000000000821","article-title":"Development of a high-throughput quantification method for pazopanib using ultra-performance liquid chromatography-tandem mass spectrometry and its clinical application in patients with soft tissue tumors","volume":"43","author":"Shiraiwa","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2013.08.013","article-title":"A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"937","author":"van Erp","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpba.2018.03.013","article-title":"Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS\/MS","volume":"154","author":"Paludetto","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/bio.15.235","article-title":"Development and clinical validation of an LC-MS\/MS method for the quantification of pazopanib in DBS","volume":"8","author":"Verheijen","year":"2016","journal-title":"Bioanalysis"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2021.114348","article-title":"Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application","volume":"206","author":"Matsumoto","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jcph.558","article-title":"Dried blood spot analysis for therapeutic drug monitoring of pazopanib","volume":"55","author":"de Wit","year":"2015","journal-title":"J Clin Pharmacol."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1039\/c2an35082c","article-title":"Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring","volume":"137","author":"Espy","year":"2012","journal-title":"Analyst"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.heliyon.2020.e03813","article-title":"HPLC-MS\/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma","volume":"6","author":"Toh","year":"2020","journal-title":"Heliyon"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchromb.2012.02.037","article-title":"HPLC-DAD protein kinase inhibitor analysis in human serum","volume":"893","author":"Dziadosz","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","article-title":"Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2010","journal-title":"Oncologist"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1038\/bjc.2014.233","article-title":"Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies","volume":"110","author":"Tan","year":"2014","journal-title":"Br J Cancer"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archophthalmol.2009.27","article-title":"Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib","volume":"127","author":"Takahashi","year":"2009","journal-title":"Arch Ophthalmol."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10637-012-9900-0","article-title":"Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors","volume":"31","author":"Infante","year":"2013","journal-title":"Invest New Drugs"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-014-2374-3","article-title":"Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors","volume":"73","author":"Inada-Inoue","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1158\/1078-0432.CCR-11-0793","article-title":"Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics","volume":"17","author":"Yau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"E453","DOI":"10.1016\/j.clgc.2016.03.016","article-title":"Pharmacokinetic analysis of a hemodialyzed patient treated with pazopanib","volume":"14","author":"Noda","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1535-7163.MCT-11-0997","article-title":"Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors","volume":"11","author":"Burris","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1078155219841108","article-title":"Clinical outcomes and toxicities of pazopanib administered orally in crushed form: case reports and review of the literature","volume":"26","author":"Stein","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1535-7163.MCT-14-0431","article-title":"A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors","volume":"14","author":"Kendra","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10637-014-0142-1","article-title":"A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer","volume":"33","author":"Bennouna","year":"2015","journal-title":"Invest New Drugs"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12885-020-6708-8","article-title":"Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies","volume":"20","author":"Sheng","year":"2020","journal-title":"BMC Cancer"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2217\/fon-2017-0083","article-title":"The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape","volume":"13","author":"Goebell","year":"2017","journal-title":"Future Oncol"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1158\/1078-0432.CCR-11-1734","article-title":"The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use","volume":"17","author":"Nieto","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12874-022-01676-9","article-title":"Informed Bayesian survival analysis","volume":"22","author":"Barto\u0161","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eurj Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:28Z","timestamp":1748970868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001206","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2023-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}